Novartis Ag

Leo Widler

Sven Weiler

Marc Gerspacher

Eva Altmann

Johanne Renaud

Rene Beerli

Ruben Alberto Tommasi

Marina Tintelnot-Blomley

Joerg Kallen

Joachim Nozulak

Simona Cotesta

Christina Hebach

Wolfgang Jahnke

René Beerli

Jean Michel Rondeau

Marina Tintelnot-blomley

The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or diabetes/metabolic syndrome via inhibition of HDAC4. 

Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

A compound of formula (1): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives

Use of compound of formula (I), wherein, is, or, and wherein the symbols are as defined, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, for the preparation of a medicament for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Quinazoline derivatives which promote the release of parathyroid hormone

C-C-Alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of Rand Ris hydrogen and the other is C-C-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.

[object Object]

A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable. 

Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives

Growing community of inventors

Muenchenstein, Switzerland

Leo Widler